Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00779922|
Recruitment Status : Completed
First Posted : October 24, 2008
Last Update Posted : October 11, 2016
The purpose of this study is to determine the pharmacokinetic profile of Revlimid® in patients presenting with Multiple Myeloma and impaired renal function, the safety of Revlimid® in the enrolled patients population.
and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM and impaired renal function at completion of 3 cycles of treatment.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma Impaired Renal Function||Drug: lenalidomide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||39 participants|
|Study Start Date :||November 2008|
|Actual Primary Completion Date :||September 2012|
U.S. FDA Resources
|Experimental: group 1 to 5||Drug: lenalidomide|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00779922
|Poitiers University Hospital|
|Poitiers, France, 86000|